Aduro BioTech Inc (NASDAQ:ADRO) insider Elsas Andrea Van sold 6,081 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $3.96, for a total transaction of $24,080.76. Following the completion of the transaction, the insider now owns 239,557 shares in the company, valued at $948,645.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Elsas Andrea Van also recently made the following trade(s):

  • On Tuesday, February 26th, Elsas Andrea Van sold 6,844 shares of Aduro BioTech stock. The shares were sold at an average price of $4.25, for a total transaction of $29,087.00.
  • On Friday, December 28th, Elsas Andrea Van sold 1,907 shares of Aduro BioTech stock. The shares were sold at an average price of $2.57, for a total transaction of $4,900.99.
  • On Friday, December 28th, Elsas Andrea Van sold 1,907 shares of Aduro BioTech stock. The shares were sold at an average price of $2.57, for a total transaction of $4,900.99.

Shares of ADRO stock traded down $0.04 during trading hours on Thursday, hitting $3.87. The company had a trading volume of 282,500 shares, compared to its average volume of 789,124. Aduro BioTech Inc has a fifty-two week low of $2.34 and a fifty-two week high of $9.85. The firm has a market cap of $310.87 million, a P/E ratio of -3.34 and a beta of 2.08.

Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.10). Aduro BioTech had a negative return on equity of 54.84% and a negative net margin of 632.05%. Analysts forecast that Aduro BioTech Inc will post -0.78 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of ADRO. Baillie Gifford & Co. lifted its holdings in shares of Aduro BioTech by 19.0% in the 4th quarter. Baillie Gifford & Co. now owns 3,661,173 shares of the biotechnology company’s stock worth $9,665,000 after acquiring an additional 584,348 shares during the last quarter. Artal Group S.A. lifted its holdings in shares of Aduro BioTech by 81.8% in the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock worth $2,640,000 after acquiring an additional 450,000 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Aduro BioTech by 8.8% in the 3rd quarter. BlackRock Inc. now owns 5,121,243 shares of the biotechnology company’s stock worth $37,640,000 after acquiring an additional 414,717 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Aduro BioTech by 1,227.1% in the 4th quarter. Two Sigma Investments LP now owns 445,929 shares of the biotechnology company’s stock worth $1,177,000 after acquiring an additional 412,327 shares during the last quarter. Finally, Vanguard Group Inc lifted its holdings in shares of Aduro BioTech by 9.9% in the 3rd quarter. Vanguard Group Inc now owns 4,029,445 shares of the biotechnology company’s stock worth $29,617,000 after acquiring an additional 362,516 shares during the last quarter. Hedge funds and other institutional investors own 44.73% of the company’s stock.

Several equities analysts have weighed in on the stock. Zacks Investment Research reiterated a “hold” rating on shares of Aduro BioTech in a report on Monday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $8.30 target price on shares of Aduro BioTech in a report on Wednesday, December 19th. Oppenheimer reiterated a “buy” rating on shares of Aduro BioTech in a report on Tuesday. Finally, BidaskClub upgraded shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Aduro BioTech presently has an average rating of “Hold” and an average target price of $7.41.

WARNING: “Aduro BioTech Inc (ADRO) Insider Elsas Andrea Van Sells 6,081 Shares” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2019/03/21/aduro-biotech-inc-adro-insider-elsas-andrea-van-sells-6081-shares.html.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Article: What is a good rate of return for a mutual fund?

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.